Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MSC-1 · 1 trial · 4 indications
Assessment of frequency \& severity of adverse events
Determine objective response rate (ORR)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Multiple dose levels of MSC-1 treatment once every 3 weeks |
| Dose Expansion | EXPERIMENTAL | MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks |
| Name | Type | Description |
|---|---|---|
| MSC-1 | BIOLOGICAL | humanized monoclonal antibody for intravenous administration |
Inclusion Criteria (All patients): * Confirmed Advanced Unresectable Solid Tumor * Measurable disease by RECIST 1.1 by CT or MRI * Documented disease progression on or following last line of therapy * Archival tumor sample for submission * ECOG performance status 0 or 1 * Resolution of all acute, r...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MSC-1 is an investigational monoclonal antibody being developed for the treatment of advanced solid tumors, including pancreatic cancer, non-small cell lung cancer, and ovarian cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MSC-1 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for its safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity in patients with advanced solid tumors.
MSC-1 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's potential in treating advanced solid tumors.
MSC-1 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational. It has not received FDA approval and is still undergoing clinical evaluation for safety and efficacy in patients with advanced solid tumors.
MSC-1 has been studied in one clinical trial, identified as NCT03490669, which was a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MSC-1 in patients with advanced solid tumors. The trial was completed and enrolled 41 participants.